The latest clinical research in oncology — curated and analysed by AI, with special focus on cancer diagnosis, novel treatments, and AI applications.
Weekly on Mondays · No spam · Unsubscribe any time
Latest Issue
2026-05-26
Tebentafusp's phase III overall survival benefit in uveal melanoma validates TCR-based immune redirection as a new treatment paradigm, while a wave of MRD-guided, biomarker-selected, and circadian-timed trials signals oncology's accelerating shift from histology-driven to molecular-state-driven care.
Read this issue →